Baxter Healthcare Corporation of Puerto Rico v. United States

182 F.3d 1333, 1999 WL 450685
CourtCourt of Appeals for the Federal Circuit
DecidedSeptember 20, 1999
Docket98-1343
StatusPublished
Cited by88 cases

This text of 182 F.3d 1333 (Baxter Healthcare Corporation of Puerto Rico v. United States) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Baxter Healthcare Corporation of Puerto Rico v. United States, 182 F.3d 1333, 1999 WL 450685 (Fed. Cir. 1999).

Opinions

Opinion for the court filed by Circuit Judge LOURIE. Dissenting opinion filed by Circuit Judge NEWMAN.

LOURIE, Circuit Judge.

Baxter Healthcare appeals from the February 24, 1998 decision of the United States Court of International Trade denying its motion for summary judgment and granting the United States’ cross-motion for summary judgment that the United States Customs Service (Customs) correctly classified its imported Oxyphan® product under subheading 5404.10.80, Harmonized Tariff Schedule of the United States, 19 U.S.C. § 1202 (1994) (HTSUS). See Baxter Healthcare Corp. of Puerto Rico v. United States, 998 F.Supp. 1133 (C.I.T.1998). Because we conclude that Customs correctly classified the merchandise, we affirm.

BACKGROUND

Between 1992 and 1994, Baxter bought and imported a product known as Oxy-phan® in ten-kilometer spool units from Akzo Nobel Faser AG (Akzo) in Germany. Oxyphan® is a 0.4 mm-diameter polypropylene filament with a linear density greater than 67 decitex. However, it has characteristics unique among filaments in that it is hollow, it has a capillary-sized diameter, its microporous walls are gas-permeable, it has low tensile strength, and it does not undergo a drawing step during manufacturing. Akzo specifically designed Oxyphan® with these characteristics in mind for use as the gas-exchanging membrane of an oxygenator.1 It has no. other known use. Baxter uses Oxyphan® to make its Univox® membrane oxygenator product. To make an oxygenator, Baxter groups seven or eight lengths of Oxy-phan®, ties them together, wraps them around a cylindrical steel bellow twenty-two times, and encloses the assembly in a polycarbonate manifold with two sets of inlet and outlet ports. Each spool of Oxy-phan® membrane contains enough membrane to make approximately four oxygen-ators, but the exact length of membrane required per oxygenator is not fixed. During operation, oxygen-deficient blood is pumped around the Oxyphan® membranes while oxygen is simultaneously pumped through the membranes. Because the membrane is gas-permeable, oxygen diffuses out of the membrane hollows into the blood, and carbon dioxide diffuses from the blood into the membrane hollows and out an exit port.

At issue in this case is Oxyphan®’s proper classification in the HTSUS. The parties dispute which of the following headings and subheadings constitutes the proper classification for Oxyphan®:

5404 Synthetic monofilament of 67 de-citex or more and of which no cross-sectional dimension exceeds 1 mm; strip and the like (for example, artificial straw) of synthetic textile materials of an apparent width not exceeding 5 mm:
5404.10 Monofilament:
* * *
5404.10.80 Other
* * *
* * *
9018 Instruments and appliances used in medical, surgical, dental or [1336]*1336veterinary sciences, including scintigraphic apparatus, other electro-medical apparatus and sight-testing instruments; parts and accessories thereof:
9018.90 Other instruments and appliances and parts and accessories thereof:
* * *
Other
* * *
Electro-medical instruments and appliances and parts and accessories thereof:
9018.90.60 Electro-surgical instruments and appliances, other than extracorporeal shock wave lithotripters; all the foregoing and parts and accessories thereof
9018.90.70 Other
* * *
* * *
9019 Mechano-therapy appliances; massage apparatus; psychological aptitude-testing apparatus; ozone therapy, oxygen therapy, aerosol therapy, artificial respiration or other therapeutic respiration apparatus; parts and accessories thereof:
* * .1!
9019.20.00 Ozone therapy, oxygen therapy, aerosol therapy, artificial respiration or other therapeutic respiration apparatus; parts and accessories thereof

HTSUS (1994 ed.).2

Customs classified Oxyphan® under subheading 5404.10.80 and liquidated it at the corresponding general duty rate of 7.8% ad valorem. See Baxter, 998 F.Supp. at 1135. Baxter timely protested Customs’ classification, which protest was denied. See United States Customs Service Headquarters Ruling Letter No. 950047- (Dec. 3, 1991). Baxter then challenged Customs’ classification in the Court of International Trade. It asked the court to order Customs to reliquidate its Oxyphan® entries either under subheading 9019.20.00, as a “part” .of an “artificial respiration apparatus,” at the corresponding 3.7% general duty rate, or under subheading 9018.90.70, as a “part” of an “other” “electro-medical instrument or appliance,” at 4.2%, and to refund the excess duty with interest. See Baxter, 998 F.Supp. at 1135. The government responded that Customs either correctly classified Oxyphan® under subheading 5404.10.80, or that it should have classified it under subheading 9018.90.60, as a “part” of an “electro-surgical instrument or appliance,” and liquidated it at 7.9%. See id. at 1137.

Baxter and the government each cross-moved for summary judgment. See id. at 1135. The court held that Customs correctly classified Oxyphan® as a synthetic monofilament because it was both “synthetic” and a “monofilament” as both those terms are defined by the Notes in the HTSUS, the Explanatory Notes, several general and technical dictionaries, and Baxter’s expert witnesses. See id. at 1139-45. The court in fact relied heavily on Baxter’s expert witnesses. The court further reasoned that Customs properly classified Oxyphan® as an independent article, not as a “part” or “unfinished part,” [1337]*1337because its use as a “part” of an oxygenator could not be discerned at the time of import and because each spool of Oxy-phan® underwent substantial processing— cutting, intertwining with another monofi-lament, wrapping around a bellow, and further cutting — before it obtained . the character of an oxygenator “part.” See id. at 1145-49. The court rejected Baxter’s argument that Customs should have classified Oxyphan® as a “part” of an artificial respiration apparatus for the further reason that Baxter’s' oxygenator did not perform the mechanical breathing function common to other artificial respiration apparatuses. See id. at 1149-50.

Baxter timely appealed to this court. We have jurisdiction pursuant to 28 U.S.C. § 1295(a)(5) (1994).

DISCUSSION

A. Standard of Review

We review the Court of International Trade’s grant of summary judgment in a trade classification case for correctness as a matter of law, deciding de novo whether genuine issues of material fact exist.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cozy Comfort Co., LLC v. United States
2025 CIT 75 (Court of International Trade, 2025)
Ildico Inc. v. United States
2024 CIT 123 (Court of International Trade, 2024)
Keystone Auto. Operations, Inc. v. United States
732 F. Supp. 3d 1339 (Court of International Trade, 2024)
HyAxiom, Inc. v. United States
726 F. Supp. 3d 1398 (Court of International Trade, 2024)
Blue Sky the Color of Imagination, LLC v. United States
698 F. Supp. 3d 1243 (Court of International Trade, 2024)
Rkw Klerks Inc. v. United States
94 F.4th 1374 (Federal Circuit, 2024)
Jing Mei Automotive (USA) v. United States
2023 CIT 180 (Court of International Trade, 2023)
Vecoplan, LLC v. United States
675 F. Supp. 3d 1263 (Court of International Trade, 2023)
Nutricia N. Am., Inc. v. United States
666 F. Supp. 3d 1363 (Court of International Trade, 2023)
Nature's Touch Frozen Foods (West) Inc. v. United States
2023 CIT 82 (Court of International Trade, 2023)
ME Global, Inc. v. United States
633 F. Supp. 3d 1349 (Court of International Trade, 2023)
Shamrock Bldg. Materials, Inc. v. United States
619 F. Supp. 3d 1337 (Court of International Trade, 2023)
SGS Sports Inc. v. United States
620 F. Supp. 3d 1365 (Court of International Trade, 2023)
S.C. Johnson & Son, Inc. v. United States
2019 CIT 158 (Court of International Trade, 2019)
FANUC Robotics Am., Inc. v. United States
2019 CIT 94 (Court of International Trade, 2019)
Moen Inc. v. United States
294 F. Supp. 3d 1337 (Court of International Trade, 2018)
Quaker Pet Grp., LLC v. United States
2018 CIT 9 (Court of International Trade, 2018)
Quaker Pet Group, LLC v. United States
287 F. Supp. 3d 1348 (Court of International Trade, 2018)
Kalle USA, Inc. v. United States
273 F. Supp. 3d 1319 (Court of International Trade, 2017)
Rubies Costume Co. v. United States
2017 CIT 147 (Court of International Trade, 2017)

Cite This Page — Counsel Stack

Bluebook (online)
182 F.3d 1333, 1999 WL 450685, Counsel Stack Legal Research, https://law.counselstack.com/opinion/baxter-healthcare-corporation-of-puerto-rico-v-united-states-cafc-1999.